BACKGROUND & AIMS: Rb1 encodes a cell-cycle regulator that is functionally disrupted in most human cancers. Pancreatic ductal adenocarcinomas (PDACs) have a high frequency of mutations in KRAS and INK4A/CDKN2A that might allow cells to bypass the regulatory actions of retinoblastoma (RB). To determine the role of loss of RB function in PDAC progression, we investigated the effects of Rb disruption during pancreatic malignant transformation initiated by oncogenic Kras. METHODS: We generated mice with pancreas-specific disruption of Rb, in the absence or presence of oncogenic Kras, to examine the role of RB in pancreatic carcinogenesis. RESULTS: In the presence of oncogenic Kras, loss of Rb from the pancreatic epithelium accelerated formation of pancreatic intraepithelial neoplasia (PanIN), increased the frequency of cystic neoplasms, and promoted rapid progression toward PDAC. Early stage cancers were characterized by acute pancreatic inflammation, associated with up-regulation of proinflammatory cytokines within the pancreas. Despite the presence of markers associated with oncogene-induced senescence, low-grade PanIN were highly proliferative and expressed high levels of p53. Pancreatic cancer cell lines derived from these mice expressed high levels of cytokines, and transcriptional activity of p53 was impaired. CONCLUSIONS: Rb encodes a tumor suppressor that attenuates progression of oncogenic Kras-induced carcinogenesis in the pancreas by mediating the senescence response and promoting activity of the tumor suppressor p53.
BACKGROUND & AIMS:Rb1 encodes a cell-cycle regulator that is functionally disrupted in most humancancers. Pancreatic ductal adenocarcinomas (PDACs) have a high frequency of mutations in KRAS and INK4A/CDKN2A that might allow cells to bypass the regulatory actions of retinoblastoma (RB). To determine the role of loss of RB function in PDAC progression, we investigated the effects of Rb disruption during pancreatic malignant transformation initiated by oncogenic Kras. METHODS: We generated mice with pancreas-specific disruption of Rb, in the absence or presence of oncogenic Kras, to examine the role of RB in pancreatic carcinogenesis. RESULTS: In the presence of oncogenic Kras, loss of Rb from the pancreatic epithelium accelerated formation of pancreatic intraepithelial neoplasia (PanIN), increased the frequency of cystic neoplasms, and promoted rapid progression toward PDAC. Early stage cancers were characterized by acute pancreatic inflammation, associated with up-regulation of proinflammatory cytokines within the pancreas. Despite the presence of markers associated with oncogene-induced senescence, low-grade PanIN were highly proliferative and expressed high levels of p53. Pancreatic cancer cell lines derived from these mice expressed high levels of cytokines, and transcriptional activity of p53 was impaired. CONCLUSIONS:Rb encodes a tumor suppressor that attenuates progression of oncogenic Kras-induced carcinogenesis in the pancreas by mediating the senescence response and promoting activity of the tumor suppressor p53.
Authors: Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho Journal: Genes Dev Date: 2003-12-17 Impact factor: 11.361
Authors: W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang Journal: Cancer Res Date: 1994-03-01 Impact factor: 12.701
Authors: Carmen Guerra; Alberto J Schuhmacher; Marta Cañamero; Paul J Grippo; Lena Verdaguer; Lucía Pérez-Gallego; Pierre Dubus; Eric P Sandgren; Mariano Barbacid Journal: Cancer Cell Date: 2007-03 Impact factor: 31.743
Authors: Jennifer P Morton; Nigel B Jamieson; Saadia A Karim; Dimitris Athineos; Rachel A Ridgway; Colin Nixon; Colin J McKay; Ross Carter; Valerie G Brunton; Margaret C Frame; Alan Ashworth; Karin A Oien; T R Jeffry Evans; Owen J Sansom Journal: Gastroenterology Date: 2010-05-06 Impact factor: 22.682
Authors: Jean-Philippe Coppé; Christopher K Patil; Francis Rodier; Yu Sun; Denise P Muñoz; Joshua Goldstein; Peter S Nelson; Pierre-Yves Desprez; Judith Campisi Journal: PLoS Biol Date: 2008-12-02 Impact factor: 8.029
Authors: Andreas M Heilmann; Rushika M Perera; Veronika Ecker; Brandon N Nicolay; Nabeel Bardeesy; Cyril H Benes; Nicholas J Dyson Journal: Cancer Res Date: 2014-07-01 Impact factor: 12.701
Authors: Atsuo Ochi; Christopher S Graffeo; Constantinos P Zambirinis; Adeel Rehman; Michael Hackman; Nina Fallon; Rocky M Barilla; Justin R Henning; Mohsin Jamal; Raghavendra Rao; Stephanie Greco; Michael Deutsch; Marco V Medina-Zea; Usama Bin Saeed; Melvin O Ego-Osuala; Cristina Hajdu; George Miller Journal: J Clin Invest Date: 2012-11 Impact factor: 14.808
Authors: Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc Journal: Mol Cancer Ther Date: 2013-11-26 Impact factor: 6.261
Authors: Jesse Gore; Imade E Imasuen-Williams; Abass M Conteh; Kelly E Craven; Monica Cheng; Murray Korc Journal: Cancer Lett Date: 2016-06-03 Impact factor: 8.679
Authors: Howard Donninger; M Lee Schmidt; Jessica Mezzanotte; Thibaut Barnoud; Geoffrey J Clark Journal: Semin Cell Dev Biol Date: 2016-06-08 Impact factor: 7.727